Rodger, AJ, et al.
Assessment of long term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971–1975. Hepatology
2000; 32: 582–587.
Maher, L, et al.
Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction
2006; 101: 1499–1508.
Grebely, J, et al.
Reinfection with hepatitis C virus following sustained virological response in injection drug users. Journal of Gastroenterology and Hepatology
2010; 25: 1281–1284.
Bell, J, et al.
Hepatitis C in intravenous drug users. Medical Journal of Australia
1990; 153: 274–276.
Iversen, J, et al.
Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. American Journal of Public Health
2013; 103: 1436–1444.
Dietze, P, Fitzgerald, J. Interpreting changes in heroin supply in Melbourne: droughts, gluts or cycles?
Drug and Alcohol Review
2002; 21: 295–303.
Higgs, P, Maher, L. Older injectors: an emerging and under-recognised public health issue. Drug and Alcohol Review
2010; 29: 233–234.
White, B, et al.
Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study. Medical Journal of Australia
2014; 201: 326–329.
Nolan, S, et al.
The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction
Grebely, J, et al.
Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996–2012. PLoS ONE
2014; 9: e97726.
Turner, KM, et al.
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction
2011; 106: 1978–1988.
Horyniak, D, et al.
Establishing the Melbourne Injecting Drug User Cohort Study (MIX): rationale, methods, and baseline and twelve-month follow-up results. Harm Reduction Journal
2013; 10: 11.
Heckathorn, DD. Respondent-driven sampling: a new approach to the study of hidden populations. Social Problems
1997; 44: 174–199.
Aitken, CK, et al.
Molecular epidemiology of hepatitis C virus in a social network of injection drug users. Journal of Infectious Diseases
2004; 190: 1586–1595.
Fry, CL, et al.
The ethics of paying drug users who participate in research: a review and practical recommendations. Journal of Empirical Research on Human Research Ethics
2006; 1: 21–36.
Allison, PD. Event History and Survial Analysis, 2nd edn.
Thousand Oaks, California, USA: Sage, 2014.
Weesie, J. Seemingly unrelated estimation and the cluster-adjusted sandwich estimator. Stata Technical Bulletin
52: 34–47. Reprinted in Stata Technical Bulletin Reprints 9, pp. 231–248. College Station, TX: Stata Press.
Huber, PJ. The behavior of maximum likelihood estimates under nonstandard conditions. Ffifth Berkeley Symposium on Mathematical Statistics and Probability. Berkeley, CA: University of California Press, 1967, pp. 221–233.
StataCorp. Stata Statistical Software: Release 13. College Station, Texas, USA: StataCorp LP, 2013.
Aitken, CK, et al.
High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology
2008; 48: 1746–1752.
McDonald, SA, et al.
Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow. International Journal on Drug Policy
2012; 23: 353–357.
Hagan, H, et al.
A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. Journal of Infectious Diseases
2011; 204: 74–83.
Des Jarlais, DC. Commentary on Zhou et al. (2015): Research on methadone maintenance treatment (MMT) as prevention for HCV infection – MMT is not a single variable. Addiction
2015; 110: 803–804.